Safety Evaluation of Tarlatamab in SCLC: A Systematic Review and Meta-Analysis
Elsa Vitale, Lorenza Maistrello, Alessandro Rizzo, Domenico Galetta, Vito Longo · 2026
Read Safety Evaluation of Tarlatamab in SCLC: A Systematic Review and Meta-Analysis by Elsa Vitale, Lorenza Maistrello, Alessandro Rizzo, Domenico Galetta, Vito Longo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13524861.txt.
Description
A new immune drug for small cell lung cancer, tarlatamab, helps T cells attack tumor cells but brings its own pattern of side effects. Elsa Vitale and co-authors pooled the safety results of the early trials in 2026. Four studies with 457 patients fed their combined analysis of treatment-related harms.
Severe side effects were common, affecting about two in five patients, and a similar share had serious events. A fever-and-inflammation reaction called cytokine release syndrome occurred in over half the patients, while appetite loss, fever, and altered taste each hit about a third. Few patients stopped treatment for side effects. The authors call for research on who is at risk and how to prevent the worst reactions.
Catalog record
| CREATOR | Elsa Vitale, Lorenza Maistrello, Alessandro Rizzo, Domenico Galetta, Vito Longo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |